- Chesner, Lisa N;
- Polesso, Fanny;
- Graff, Julie N;
- Hawley, Jessica E;
- Smith, Alexis K;
- Lundberg, Arian;
- Das, Rajdeep;
- Shenoy, Tanushree;
- Sjöström, Martin;
- Zhao, Faming;
- Hu, Ya-Mei;
- Linder, Simon;
- Chen, William S;
- Hawkins, Reed M;
- Shrestha, Raunak;
- Zhu, Xiaolin;
- Foye, Adam;
- Li, Haolong;
- Kim, Lisa M;
- Bhalla, Megha;
- O’loughlin, Thomas;
- Kuzuoglu-Ozturk, Duygu;
- Hua, Junjie T;
- Badura, Michelle L;
- Wilkinson, Scott;
- Trostel, Shana Y;
- Bergman, Andries M;
- Ruggero, Davide;
- Drake, Charles G;
- Sowalsky, Adam G;
- Fong, Lawrence;
- Cooperberg, Matthew R;
- Zwart, Wilbert;
- Guan, Xiangnan;
- Ashworth, Alan;
- Xia, Zheng;
- Quigley, David A;
- Gilbert, Luke A;
- Feng, Felix Y;
- Moran, Amy E
Significance
Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.